Brief: Immutep Ltd Says FDA Granted Orphan Drug Designation For Eftilagimod alfa In Soft Tissue Sarcoma
15/04/2026 02:21
April 15 (Reuters) - Immutep Ltd IMM.AX: IMMUTEP LTD - FDA GRANTS ORPHAN DRUG DESIGNATION FOR EFTILAGIMOD ALFA IN SOFT TISSUE SARCOMA Source text: ID:nASX4fL5nr Further company coverage: IMM.AX
Recent news on Immutep
See all newsBrief: Immutep Receives NASDAQ Notice Of Minimum Bid Price Non-Compliance
Australia's Immutep extends gain on FDA orphan drug status for cancer drug
Brief: Immutep Ltd Says FDA Granted Orphan Drug Designation For Eftilagimod alfa In Soft Tissue Sarcoma
Brief: Immutep Discontinues Phase III Tacti-004 Study In Non-Small Cell Lung Cancer
Brief: Dr Reddy's Says IDMC Recommends Discontinuation Of TACTI-004 Phase III Trial After Interim Futility Analysis